BioVersys AG ( (CH:BIOV) ) has shared an update.
BioVersys AG announced its participation in the 35th ESCMID Global 2025 conference, where it will present positive Phase 2 trial results for its BV100 treatment, which shows promise against carbapenem-resistant Acinetobacter baumannii (CRAB) infections. The data highlights BV100’s potential as a game-changer in treating these infections, with significant survival benefits observed, positioning BioVersys as a key player in the fight against antibiotic-resistant superbugs.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products to combat serious infections caused by multidrug-resistant bacteria. The company is dedicated to addressing the global challenge of antibiotic resistance, with a particular emphasis on life-threatening infections.
YTD Price Performance: -0.14%
Average Trading Volume: 7,192
See more insights into BIOV stock on TipRanks’ Stock Analysis page.